Proliant Health & Biologicals Raises the Albumin Standard with AlbufreeDX: Consistent, Animal-Free Recombinant Human Albumin

AlbufreeDX is a diagnostic-grade, animal-free recombinant human albumin (rHA) launched by Proliant Health & Biologicals to meet the biotechnology market's demand for high-purity ingredients.

Proliant Health & Biologicals, a worldwide leader in purified proteins, announced the commercial launch of AlbufreeDX, a recombinant human albumin (rHA) intended to meet the increasing demand for high-performance, animal-free ingredients in the diagnostic and life science applications.

For more than two decades, Proliant has been a trusted producer of albumin and other purified proteins, serving consistent quality and dependable supply globally. Headquartered in Ankeny, Iowa, with production locations in the United States and New Zealand, Proliant continues to expand its abilities to support biotechnology, diagnostics, and medical care markets.

Albumin is broadly used in diagnostics, pharmaceutical production, and research workflows for its capability to stabilize proteins, avoid undesirable surface binding, and enhance assay performance and reproducibility. As diagnostic assays emerge toward novel analytes, increasing sensitivity, and throughput platforms, raw materials must deliver advanced consistency and purity to prevent variability and signal interference. Traditional animal- or human-derived albumins introduce added testing needs, traceability load, and regulatory challenges.

Dr. Christopher Warner, Vice President of Research and Development, stated, "IVD companies are prioritizing animal- and human-origin-free devices to reduce regulatory complexity across regions. AlbufreeDX supports this strategy by enabling streamlining global and IVDR compliance while helping companies meet ESG commitments."

Produced via precision fermentation, AlbufreeDX supplies advanced purity, dependable performance, and outstanding lot-to-lot reproducibility. It is well suited for applications involving protein stabilization, surface blocking, reagent formulation, and reference standards, specifically where reducing variability and avoiding the challenges of animal-derived pathogens are significant.

"As our customers' requirements have evolved, so has our portfolio," said Dr. Christopher Detzel, President and CEO. "AlbufreeDX is a natural extension of our strengths, offering an animal-free albumin option while maintaining the consistency, reliability, and scale our customers expect."

The launch of AlbufreeDX strengthens Proliant's increasing life science portfolio, with future products involving AlbufreeTX for cell culture and AlbufreeCGT to help evolving cell and gene therapy workflows.

According to Towards Healthcare, the recombinant albumin market is projected to grow significantly, with estimates indicating the market size will increase from USD 162.2 million in 2026 to approximately USD 275.89 million by 2035, experiencing a CAGR of 6.08% over the next 10 years. It is clinically applied in the management of serious hypoalbuminemia and as a plasma expander. The application of albumins as a carrier for therapeutics is presently being developed, and some are now in the preclinical and clinical trial stages. The important technologies for applying albumin as a therapeutic carrier are protein fusion, polymerization, and surface modification. It plays a significant role in the advancement of cell culture media, biologics, vaccines, drug delivery systems, and regenerative therapeutics.  The applications of recombinant human albumin in biopharmaceutical formulation offer many of the recognized advantages of using human serum albumin as an excipient, whilst preventing the challenges of transmitting viral and prion contaminants. It is one of the most widely used proteins in coatings for healthcare tools and as a component in widely used proteins in the pharmaceutical industry. Its major healthcare applications involve stabilizing vaccines and biologics, providing a growth supplement in cell and gene therapies, acting as a drug delivery transporter, and coating healthcare devices.

About Merck Animal Health

The Proliant Health Biologicals team is driven by the knowledge that there are continuous opportunities to revolutionize. Their promise of quality, world-class support, and on-time distributions has exceeded expectations. Their team has experience working with an array of collaborations and tackling a variety of specific requirements and complexities. Those challenges are often complex and need precise services that fit tight stipulations. Proliant Health & Biologicals, often abbreviated PHB, is a protein-ingredient and purified-protein producer serving microbiological, life-science, pharmaceutical, veterinary, diagnostic, cell-culture, and nutrition customers worldwide. PHB's core producing focus is high-purity protein production for uses where lot consistency, traceability, and reliability affect diagnostic or bioprocess performance. The organization says it controls its production technology for diagnostic protein products and highlights BSA purity as significant for diagnostic precision.

A recent report by Towards Healthcare highlights that the recombinant albumin market is growing, as significant benefits of recombinant albumin involve its lack of strong human contaminants and infectious agents. Recombinant albumin enhances recovery and preserves the bioactivity of dilute cytokines as compared with albumin-free formulations.  rAlbumin is a purified and well-characterized therapeutic, offering all the advantages of albumin without the regulatory challenges and risks related to serum-derived albumin. Recombinant HA is a safe, promising, and consistent substitute for plasma-derived HSA, with strong applications increasing beyond biopharmaceutical stabilization to therapeutic applications in significantly ill patients. The effective integration of rHA in healthcare practice could have an important impact on medical care beyond the treatment of patients with cirrhosis and sepsis.